4//SEC Filing
Sofinnova Venture Partners IX, L.P. 4
Accession 0001144204-19-026681
CIK 0001661059other
Filed
May 14, 8:00 PM ET
Accepted
May 15, 5:59 PM ET
Size
26.7 KB
Accession
0001144204-19-026681
Insider Transaction Report
Form 4
NextCure, Inc.NXTC
Sofinnova Venture Partners IX, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2019-05-13+469,713→ 2,121,856 total - Purchase
Common Stock
2019-05-13$15.00/sh+400,000$6,000,000→ 2,521,856 total - Conversion
Common Stock
2019-05-13+908,785→ 1,652,143 total - Conversion
Common Stock
2019-05-13+278,759→ 278,759 total - Conversion
Common Stock
2019-05-13+464,599→ 743,358 total - Conversion
Series A-1 Preferred Stock
2019-05-13−2,239,500→ 0 total→ Common Stock (278,759 underlying) - Conversion
Series A-2 Preferred Stock
2019-05-13−3,732,500→ 0 total→ Common Stock (464,599 underlying) - Conversion
Series A-3 Preferred Stock
2019-05-13−7,301,000→ 0 total→ Common Stock (908,785 underlying) - Conversion
Series B-1 Preferred Stock
2019-05-13−3,773,585→ 0 total→ Common Stock (469,713 underlying)
Sofinnova Management IX, L.L.C.
10% Owner
Transactions
- Conversion
Common Stock
2019-05-13+278,759→ 278,759 total - Conversion
Common Stock
2019-05-13+464,599→ 743,358 total - Conversion
Common Stock
2019-05-13+908,785→ 1,652,143 total - Conversion
Common Stock
2019-05-13+469,713→ 2,121,856 total - Purchase
Common Stock
2019-05-13$15.00/sh+400,000$6,000,000→ 2,521,856 total - Conversion
Series A-1 Preferred Stock
2019-05-13−2,239,500→ 0 total→ Common Stock (278,759 underlying) - Conversion
Series A-2 Preferred Stock
2019-05-13−3,732,500→ 0 total→ Common Stock (464,599 underlying) - Conversion
Series A-3 Preferred Stock
2019-05-13−7,301,000→ 0 total→ Common Stock (908,785 underlying) - Conversion
Series B-1 Preferred Stock
2019-05-13−3,773,585→ 0 total→ Common Stock (469,713 underlying)
HEALY JAMES
10% Owner
Transactions
- Conversion
Common Stock
2019-05-13+278,759→ 278,759 total - Conversion
Common Stock
2019-05-13+464,599→ 743,358 total - Conversion
Common Stock
2019-05-13+908,785→ 1,652,143 total - Conversion
Common Stock
2019-05-13+469,713→ 2,121,856 total - Purchase
Common Stock
2019-05-13$15.00/sh+400,000$6,000,000→ 2,521,856 total - Conversion
Series A-1 Preferred Stock
2019-05-13−2,239,500→ 0 total→ Common Stock (278,759 underlying) - Conversion
Series A-2 Preferred Stock
2019-05-13−3,732,500→ 0 total→ Common Stock (464,599 underlying) - Conversion
Series A-3 Preferred Stock
2019-05-13−7,301,000→ 0 total→ Common Stock (908,785 underlying) - Conversion
Series B-1 Preferred Stock
2019-05-13−3,773,585→ 0 total→ Common Stock (469,713 underlying)
Mehra Anand
10% Owner
Transactions
- Conversion
Common Stock
2019-05-13+278,759→ 278,759 total - Conversion
Common Stock
2019-05-13+464,599→ 743,358 total - Conversion
Common Stock
2019-05-13+908,785→ 1,652,143 total - Conversion
Common Stock
2019-05-13+469,713→ 2,121,856 total - Purchase
Common Stock
2019-05-13$15.00/sh+400,000$6,000,000→ 2,521,856 total - Conversion
Series A-1 Preferred Stock
2019-05-13−2,239,500→ 0 total→ Common Stock (278,759 underlying) - Conversion
Series A-2 Preferred Stock
2019-05-13−3,732,500→ 0 total→ Common Stock (464,599 underlying) - Conversion
Series A-3 Preferred Stock
2019-05-13−7,301,000→ 0 total→ Common Stock (908,785 underlying) - Conversion
Series B-1 Preferred Stock
2019-05-13−3,773,585→ 0 total→ Common Stock (469,713 underlying)
POWELL MICHAEL
10% Owner
Transactions
- Conversion
Common Stock
2019-05-13+278,759→ 278,759 total - Conversion
Common Stock
2019-05-13+464,599→ 743,358 total - Conversion
Common Stock
2019-05-13+908,785→ 1,652,143 total - Conversion
Common Stock
2019-05-13+469,713→ 2,121,856 total - Purchase
Common Stock
2019-05-13$15.00/sh+400,000$6,000,000→ 2,521,856 total - Conversion
Series A-1 Preferred Stock
2019-05-13−2,239,500→ 0 total→ Common Stock (278,759 underlying) - Conversion
Series A-2 Preferred Stock
2019-05-13−3,732,500→ 0 total→ Common Stock (464,599 underlying) - Conversion
Series A-3 Preferred Stock
2019-05-13−7,301,000→ 0 total→ Common Stock (908,785 underlying) - Conversion
Series B-1 Preferred Stock
2019-05-13−3,773,585→ 0 total→ Common Stock (469,713 underlying)
Footnotes (2)
- [F1]The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date.
- [F2]The shares are held directly by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.
Documents
Issuer
NextCure, Inc.
CIK 0001661059
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001612133
Filing Metadata
- Form type
- 4
- Filed
- May 14, 8:00 PM ET
- Accepted
- May 15, 5:59 PM ET
- Size
- 26.7 KB